ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPHR Sphere Medical

0.40
0.00 (0.00%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sphere Medical LSE:SPHR London Ordinary Share GB00B551W951 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.40 0.35 0.45 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Sphere Medical Holding plc Update on financing and operations (0582L)

14/07/2017 7:00am

UK Regulatory


Sphere Medical (LSE:SPHR)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Sphere Medical Charts.

TIDMSPHR

RNS Number : 0582L

Sphere Medical Holding plc

14 July 2017

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

Cambridge, UK - 14 July 2017

Sphere Medical Holding plc

("Sphere", "Sphere Medical" or the "Company")

Update on financing and operations

Financing and working capital

As announced in our Preliminary Results on 28 February 2017, the Board remains committed to the Proxima platform and is exploring its immediate financing options to ensure the Company has sufficient working capital to realise the full potential of Proxima and to maximise value for shareholders.

Having undertaken market soundings with existing shareholders and potential new investors, interest exists from a number of parties in participating in an equity fundraising, the details of which are being discussed. The Board remains focussed on the immediate financing options for the Company to secure its short and medium term working capital requirements.

Further announcements will be made in due course.

Operational update and prospects

Since the launch of Proxima 4 in December 2016 there has been a positive reaction in the market and the sales pipeline has continued to expand. The sales cycle is expected to be typically around nine months or longer. By 30 June 2017, 55 hospital departments engaged with Sphere Medical on Proxima 4 and requested evaluations, of which 38 so far have received a product demonstration. Furthermore, six customers have already placed orders within the first six months after launch.

The Board is pleased to report that the main issues surrounding the limitation on supply of Proxima 4 sensors announced on 2 May this year have been effectively addressed. Whilst this limitation constrained sales activity during the first half of this year, the Board is confident that the current improvement in sensor yields will ensure sufficient supply to meet demand for the remainder of the year and beyond.

Our three distributors in continental Europe have all now received initial supplies of Proxima 4 and have received training. Patient evaluations have also commenced in all three territories.

- Ends -

The Market Abuse Regulation ("MAR") became effective from 3 July 2016. Market Soundings, as defined in MAR, were taken in respect of the proposed Placing with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in a Market Sounding are no longer in possession of inside information relating to the Company and its securities.

For further information, please contact:

 
Sphere Medical Holding plc                       Tel: +44 (0)1223 875 
                                                                  222 
Dr Wolfgang Rencken, Chief 
 Executive Officer 
Richard Wright, Chief Financial 
 Officer 
 
Panmure Gordon                                   Tel: +44 (0) 20 7886 
                                                                 2500 
Freddy Crossley (Corporate 
 Finance) 
Duncan Monteith (Corporate 
 Finance) 
Tom Salvesen (Corporate Broking) 
 
Consilium Strategic Communications               Tel: +44 (0) 20 3709 
                                                                 5700 
Mary-Jane Elliott                   spheremedical@consilium-comms.com 
Ivar Milligan 
Rosie Phillips 
 

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is an innovative point-of-care medical device company. Its Proxima platform measures blood gases, electrolytes and metabolites at the patient's bedside and aims to improve patient care and reduce health system costs. The device is sold directly to the critical care market via Sphere Medical's sales force in the UK, Germany, The Netherlands and Belgium and via distributors in Italy, Spain and Austria. For further information, please visit www.spheremedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

UPDSFSEDDFWSELW

(END) Dow Jones Newswires

July 14, 2017 02:00 ET (06:00 GMT)

1 Year Sphere Medical Chart

1 Year Sphere Medical Chart

1 Month Sphere Medical Chart

1 Month Sphere Medical Chart

Your Recent History

Delayed Upgrade Clock